Cerus Intercept Platelet Pathogen Reduction Sets

This is a Sources Sought Notice.  This is NOT a solicitation for proposals, proposal abstracts or quotations.  The purpose of this notice is to obtain information regarding the availability and capability of qualified sources and whether or not to conduct this procurement on a competitive basis.

The NAICS code is 325413 and the size standard is 1250.  Your response to the information requested will assist the Government in determining the appropriate acquisition method.  The Government intends to award a Firm Fixed-Price purchase order to the successful quoter.  Tripler Army Medical Center (TAMC) has a requirement for Cerus Intercept Platelet Pathogen Reduction Sets.  The platelet pathogen reduction sets are used in conjunction with platelets and plasma in an Intercept processing set. The INTERCEPT Blood System uses amotosalen, a well-characterized photoactive compound that targets DNA and RNA, followed by UVA illumination which irreversibly cross-links nucleic acids. In doing so, the INTERCEPT treatment blocks replication of bacteria, viruses and parasites, rendering them inactive

Disclaimer and Important Notes:  This does not obligate the Government to award a contract or otherwise pay for the information provided in a response.  Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to supply the required products.  Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted.  No proprietary, classified, confidential or sensitive information should be included in your response.